| Clinton Jeffery Hartman, CRNA | |
|
4102 Pinion Dr, 10th Mdg, Usaf Academy, CO 80840-2502 | |
| (719) 333-5691 | |
| Not Available |
| Full Name | Clinton Jeffery Hartman |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 15 Years |
| Location | 4102 Pinion Dr, Usaf Academy, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508044207 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | R861780 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Hospital At Gulfport | Gulfport, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Etas Pllc | 8123481934 | 41 |
News Archive
Holiday dysfunction took a fatal turn this past Thanksgiving when a Florida man shot and killed four family members. According to the police sergeant in charge of the investigation, there had been "ongoing resentment" in the family.
Avicena Group has announced day that it has filed a composition of matter patent application with the United States Patent and Trademark Office (USPTO) to cover potential treatments for Huntington's disease, a fatal neurodegenerative disease.
Twitter is a place where many cancer patients go to share and discuss their experiences of the disease. This is the main finding of a recent exploratory study (1), to be presented at the ESMO 2018 Congress in Munich, which analyzed the contents of over 6,000 tweets and retweets about breast cancer.
Dr. Jean-Philippe Gratton, Director of the Endothelial cell biology research unit at the Institut de recherches cliniques de Montr-al (IRCM), identifies a new intracellular mechanism responsible for modulating vascular permeability: the nitrosylation of beta-catenin protein by nitric oxide. This scientific breakthrough could have a possible impact on the treatment of cancerous tumours by altering the permeability of the blood vessels irrigating them. Dr. Gratton's team will publish the results of its research tomorrow in the scientific journal Molecular Cell.
› Verified 3 days ago
| Entity Name | Gulf Anesthesia Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548696925 PECOS PAC ID: 8426286501 Enrollment ID: O20140117000585 |
News Archive
Holiday dysfunction took a fatal turn this past Thanksgiving when a Florida man shot and killed four family members. According to the police sergeant in charge of the investigation, there had been "ongoing resentment" in the family.
Avicena Group has announced day that it has filed a composition of matter patent application with the United States Patent and Trademark Office (USPTO) to cover potential treatments for Huntington's disease, a fatal neurodegenerative disease.
Twitter is a place where many cancer patients go to share and discuss their experiences of the disease. This is the main finding of a recent exploratory study (1), to be presented at the ESMO 2018 Congress in Munich, which analyzed the contents of over 6,000 tweets and retweets about breast cancer.
Dr. Jean-Philippe Gratton, Director of the Endothelial cell biology research unit at the Institut de recherches cliniques de Montr-al (IRCM), identifies a new intracellular mechanism responsible for modulating vascular permeability: the nitrosylation of beta-catenin protein by nitric oxide. This scientific breakthrough could have a possible impact on the treatment of cancerous tumours by altering the permeability of the blood vessels irrigating them. Dr. Gratton's team will publish the results of its research tomorrow in the scientific journal Molecular Cell.
› Verified 3 days ago
| Entity Name | Etas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679259360 PECOS PAC ID: 8123481934 Enrollment ID: O20230828000521 |
News Archive
Holiday dysfunction took a fatal turn this past Thanksgiving when a Florida man shot and killed four family members. According to the police sergeant in charge of the investigation, there had been "ongoing resentment" in the family.
Avicena Group has announced day that it has filed a composition of matter patent application with the United States Patent and Trademark Office (USPTO) to cover potential treatments for Huntington's disease, a fatal neurodegenerative disease.
Twitter is a place where many cancer patients go to share and discuss their experiences of the disease. This is the main finding of a recent exploratory study (1), to be presented at the ESMO 2018 Congress in Munich, which analyzed the contents of over 6,000 tweets and retweets about breast cancer.
Dr. Jean-Philippe Gratton, Director of the Endothelial cell biology research unit at the Institut de recherches cliniques de Montr-al (IRCM), identifies a new intracellular mechanism responsible for modulating vascular permeability: the nitrosylation of beta-catenin protein by nitric oxide. This scientific breakthrough could have a possible impact on the treatment of cancerous tumours by altering the permeability of the blood vessels irrigating them. Dr. Gratton's team will publish the results of its research tomorrow in the scientific journal Molecular Cell.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Clinton Jeffery Hartman, CRNA 4714 Ponderosa Dr, Usaf Academy, CO 80840-1233 Ph: (719) 203-6041 | Clinton Jeffery Hartman, CRNA 4102 Pinion Dr, 10th Mdg, Usaf Academy, CO 80840-2502 Ph: (719) 333-5691 |
News Archive
Holiday dysfunction took a fatal turn this past Thanksgiving when a Florida man shot and killed four family members. According to the police sergeant in charge of the investigation, there had been "ongoing resentment" in the family.
Avicena Group has announced day that it has filed a composition of matter patent application with the United States Patent and Trademark Office (USPTO) to cover potential treatments for Huntington's disease, a fatal neurodegenerative disease.
Twitter is a place where many cancer patients go to share and discuss their experiences of the disease. This is the main finding of a recent exploratory study (1), to be presented at the ESMO 2018 Congress in Munich, which analyzed the contents of over 6,000 tweets and retweets about breast cancer.
Dr. Jean-Philippe Gratton, Director of the Endothelial cell biology research unit at the Institut de recherches cliniques de Montr-al (IRCM), identifies a new intracellular mechanism responsible for modulating vascular permeability: the nitrosylation of beta-catenin protein by nitric oxide. This scientific breakthrough could have a possible impact on the treatment of cancerous tumours by altering the permeability of the blood vessels irrigating them. Dr. Gratton's team will publish the results of its research tomorrow in the scientific journal Molecular Cell.
› Verified 3 days ago
Russell Matthew Wolbers, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4102 Pinion Dr, Usaf Academy, CO 80840 Phone: 719-333-5651 | |
Lea Chien, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 4102 Pinion Dr, Usaf Academy, CO 80840 Phone: 719-333-5111 | |
Annette Susan Gablehouse, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 4102 Pinion Dr, Usaf Academy, CO 80840 Phone: 719-333-5961 | |
Dr. Lindsay B Howard, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 4102 Pinion Dr, Usaf Academy, CO 80840 Phone: 281-387-5169 | |
Stacey Alicia Vandyke, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4102 Pinion Dr, Usaf Academy, CO 80840 Phone: 719-333-5651 | |
Mrs. Krista Lynn Christianson, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4102 Pinion Dr, 10th Medical Group, Usaf Academy, CO 80840 Phone: 719-333-5691 |